Industry Research

71. Influence Of Size In CRO Selection 5/1/2019

    ISR surveyed hundreds of clinical development outsourcers about what they consider important when selecting providers. To capture the increasing role that preferred provider agreements are playing in the selection process, respondents were asked about attribute importance in several scenarios.

72. Are Outsourcers Interested In Changing Their CRO Mix? 4/1/2019

    ISR recently surveyed decision makers across all phases of clinical development to gain insight on sponsor/CRO dynamics. More than half of respondents agreed (to some level)that their organization would change its mix of CROs.

73. A Look At 2018's CDMO Expansions 12/3/2018

    ISR looked at each month in the past year to identify the biggest expansion news announced by large CDMOs.

74. The Interconnected World Of Blockbuster Oncology Drugs 11/7/2018

    A hypertree showing the network of connections between 2017’s top-selling oncology products. Oncology drugs made up 13 of last year’s top 50 selling products.

75. The Top 5 Selection Drivers For Phase IV Services 10/4/2018

    Understanding which attributes industry peers feel are important can help in the process of CRO selection.

76. Department Influence On CMO Selection 9/3/2018

    When it comes to CMO selection, Executive Management and Manufacturing/Production hold the most influence over the decision, each accounting for ~20% of control.

77. Choosing A Development-Stage eCOA/ePRO Provider 8/2/2018

    ISR asked study sponsors, CROs, and clinical research sites what’s the most important attribute they would use to select an eCOA (electronic clinical outcomes assessment)/ePRO (electronic patient reported outcomes) provider for development-stage products.

78. What Are The Largest Slices Of The 2018 CRO Market? 7/5/2018

    2017 was another strong year for CRO growth, with all major/public service providers experiencing year-over-year revenue gains. The largest component of CRO market revenue by geography, development, and service line is highlighted here.

79. Is The U.S. Biosimilar Industry Falling Behind? 6/1/2018

    Eighty-seven percent of global biosimilar sales come from the E.U., compared to just 2 percent from the U.S. We asked outsourced biomanufacturing decision-makers from North America and Europe to share their companies’ stances on selling and manufacturing biosimilars.

80. Trial Data Collection: Paper Vs. Electronic 5/2/2018

    The use of electronic data collection tools is prevalent across clinical trial phases. Respondents with visibility into Phase 4 studies report 90 to 96% of these studies use electronic data capture tools, either exclusively or as part of a hybrid EDC/paper strategy.